In breast tumor models, DCE-MRI with albumin-Gd-DTPA revealed a decreasing tumor vascular permeability surface area product after anti-angiogenic bevacizumab/paclitaxel combination therapy [58]. The gene discussed is ALB; the disease is neoplasm.